ProfileGDS5678 / 1429893_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 53% 53% 63% 63% 52% 62% 65% 63% 64% 68% 64% 63% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9006565
GSM967853U87-EV human glioblastoma xenograft - Control 23.2805253
GSM967854U87-EV human glioblastoma xenograft - Control 33.3100153
GSM967855U87-EV human glioblastoma xenograft - Control 43.7256563
GSM967856U87-EV human glioblastoma xenograft - Control 53.7609563
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3509352
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8026262
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9174365
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7517563
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8428764
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1575568
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8288664
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7928463
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3671970